The applicability of GLS inhibitors or glutamine depletion against hepatocellular carcinoma (HCC) is still at the preclinical stage, with research showing that hepatoma cells display altered sensitivity associated with self-generated adaptive mechanisms. The gene discussed is GLS; the disease is hepatocellular carcinoma.